Alfasigma has stepped up its presence in the consumer health market with the acquisition of fellow Italian firm Sofar for an undisclosed sum.
With completion of the deal – first announced in August – Bologna’s Alfasigma adds a company which grew double-digits in 2021, boasting over €113m ($111m) in sales and a portfolio of dietary supplements, OTC drugs and devices
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?